Ex-FDA Commissioner in criminal probe

7 May 2006

The former Commissioner of the US Food and Drug Administration, Lester Crawford, who resigned from his post only two months after being confirmed by the US Senate last September, is under criminal investigation according to his lawyer, Barbara Van Gelder. No details were given, but it is understood that the case involves allegations that Dr Crawford continued to hold investments in businesses that were regulated by the FDA at a time when he was the acting Commissioner.

The news emerged when Ms Van Gelder asked for a delay in court proceedings concerning the oral contraceptive Plan B (levonorgestrel, Marketletters passim) manu-factured by US drugmaker Barr Pharmaceuticals, at which Dr Crawford was asked to testify, citing the former FDA chief's own legal issues.

Von Eschenbach nomination affected

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight